Knight Therapeutics Inc.
GUD.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 37.31% | 19.11% | 15.67% | 10.60% | 8.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.31% | 19.11% | 15.67% | 10.60% | 8.76% |
| Cost of Revenue | 35.08% | 24.71% | 28.50% | 22.16% | 11.19% |
| Gross Profit | 40.03% | 12.79% | 1.91% | -1.74% | 5.95% |
| SG&A Expenses | 29.88% | 22.66% | 19.40% | 16.39% | 13.75% |
| Depreciation & Amortization | 27.56% | 9.61% | 0.62% | -9.53% | -6.82% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.45% | 22.17% | 22.45% | 15.85% | 10.03% |
| Operating Income | 3,005.35% | -128.89% | -208.10% | -206.56% | -113.47% |
| Income Before Tax | -11.71% | -478.82% | 68.90% | 68.39% | 135.62% |
| Income Tax Expenses | 207.21% | 45.36% | -391.07% | -204.87% | 69.58% |
| Earnings from Continuing Operations | -49.64% | -236.11% | 88.13% | 100.84% | 161.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.64% | -236.11% | 88.13% | 100.84% | 161.52% |
| EBIT | 3,005.35% | -128.89% | -208.10% | -206.56% | -113.47% |
| EBITDA | 49.12% | -13.36% | -32.83% | -33.71% | -8.28% |
| EPS Basic | -47.70% | -235.14% | 87.40% | 100.39% | 162.16% |
| Normalized Basic EPS | 4,466.67% | -248.36% | -257.97% | -267.27% | -103.21% |
| EPS Diluted | -51.96% | -285.25% | 83.24% | 95.02% | 155.29% |
| Normalized Diluted EPS | 4,422.22% | -248.36% | -257.97% | -267.27% | -103.21% |
| Average Basic Shares Outstanding | -1.38% | -1.46% | -1.94% | -2.80% | -4.05% |
| Average Diluted Shares Outstanding | -1.34% | -1.32% | -1.73% | -2.65% | -3.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |